Literature DB >> 29803274

Evolving Complexity in Hemophilia Management.

Stacy E Croteau1.   

Abstract

Rapid expansion of therapeutic options have increased the complexity of hemophilia care. Previously, on-demand therapy aimed to reduce morbidity and early mortality; however, now aggressive prophylaxis, particularly in children, encourages an active lifestyle. Accurate diagnosis, recognition of early threats to musculoskeletal health, and optimization of therapy are critical for both males and females affected by hemophilia. The diversity of emerging hemophilia therapies, from modified factor protein concentrates, to gene therapy, to nonfactor hemostatic strategies, provide an exciting opportunity to target unmet needs in the bleeding disorder community.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bispecific antibody; Bleeding; Factor IX; Factor VIII; Factor concentrate; Gene therapy; Hemarthrosis; Inhibitors

Mesh:

Substances:

Year:  2018        PMID: 29803274     DOI: 10.1016/j.pcl.2018.01.004

Source DB:  PubMed          Journal:  Pediatr Clin North Am        ISSN: 0031-3955            Impact factor:   3.278


  3 in total

Review 1.  Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities.

Authors:  Fatemeh Farjadian; Amir Ghasemi; Omid Gohari; Amir Roointan; Mahdi Karimi; Michael R Hamblin
Journal:  Nanomedicine (Lond)       Date:  2018-11-19       Impact factor: 5.307

2.  A Cross-National Survey of People Living with Hemophilia: Impact on Daily Living and Patient Education in Central Europe.

Authors:  Atanas Banchev; Angelika Batorova; Barbara Faganel Kotnik; Csongor Kiss; Gediminas Puras; Ester Zapotocka; Silva Zupancic-Salek
Journal:  Patient Prefer Adherence       Date:  2021-04-28       Impact factor: 2.711

Review 3.  Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life.

Authors:  Miguel A Escobar; Cindy Leissinger; Guy Young
Journal:  J Adv Pract Oncol       Date:  2022-06-21
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.